Videos

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

The orthopedic surgeron from Northwell Health discussed the expectations of physically active older patients undergoing care for joints and knees.

Patients in tocilizumab treatment group 4 times more likely to see remission.